Next Phase Newsletter

This family office is an investment fund associated with an industrial engineering firm. The firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is highly flexible in terms of investment structure, focusing on opportunities in which their engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm will invest worldwide.

The family office focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities.

The family office is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of an investment firm founded by a family office in Hong Kong is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and more. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private life science investment firm has a presence in U.K, Canada and multiple locations in U.S. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $0.5 – 3 million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized US venture capital firm under a holding group company focuses on finance, conducting business with its Chinese sister company as one group. The firm has headquarters in China and an additional virtual office in the U.S. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds. The average size of investment is ~ $5M. The firm has invested in 17 US & Canada companies since 2016. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA. The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA currently manages a $500M fund dedicated to life science investments. The firm can invest anywhere from $4-30M and invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.

The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.

The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a family office actively invests in early stage startups. Of their investments, about a third are in healthcare. The firm is a fairly opportunistic investor, and will consider therapeutics, medical device, diagnostics and digital health companies, but will only invest in companies that have a strong IP position and a strong management team. The firm generally invests in seed-series A rounds , investing $500k-3M in rounds generally in the range of $2 to $15 million. The firm prefers to invest in therapeutics companies that are IND-ready, and in device and diagnostics companies that have some clinical data. The firm will invest globally, but prefers to invest in companies based in the US.

The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies. The firm generally does not invest in consumer-facing/telehealth-related digital health companies. Historically, the firm has invested in AI-based digital health technologies, and will not invest in a digital technology that does not have strong IP. The firm is generally agnostic to indication.

The firm looks for companies with strong IP and management teams. The firm is willing to lead or co-invest, but will generally not participate in rounds larger than $30M. When acting as a lead investor, the firm is a very active investor, and plays a large role in helping company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in China and Hong Kong, manages about USD 1 billion in committed capital with five USD funds and five RMB funds. The firm typically invests in series A and B rounds; however the firm prefers seed or angel rounds when it comes to overseas opportunities. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies with excellent technology that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, e-Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within medical devices, the firm is interested in a great range of devices and disposables that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.